Trial reportGut2005
Trichuris suis therapy in Crohn's disease.
Trial report in Gut, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01734941 (A Phase 2 Randomized Three-Arm Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of 16 Weeks of Treatment With Trichuris Suis Ova), which is not on this map. Cited by 275 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Randomized Three-Arm Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of 16 Weeks of Treatment With Trichuris Suis Ova (TSO) Therapy in Pediatric Patients Ages 6 to 17 With Autism
Who cites it
275 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Unveiling the hidden threats: a review of pathogen diversity and public health risks from bats, rodents, and non-human primates in Zambia (1990-2022).Frontiers in public health · 2024Pooled it
- Use of helminth therapy for management of ulcerative colitis and Crohn's disease: a systematic review.Parasitology · 2022Pooled it
- Pooled it
- Helminth therapy (worms) for induction of remission in inflammatory bowel disease.The Cochrane database of systematic reviews · 2014Pooled it
- Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial.Inflammatory bowel diseases · 2024Trial
- A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.Journal of Crohn's & colitis · 2017Trial
- Parasites and allergies: a complex bidirectional relationship from evolutionary origins to modern therapeutics.Antonie van Leeuwenhoek · 2026Review
- Selective Packaging of miR-22 and miR-29 Orthologues into Extracellular Vesicles of the Porcine Whipworm Trichuris Suis.Journal of extracellular vesicles · 2026Article
- Tuft cells protect against intestinal inflammation through histone deacetylase 3.Mucosal immunology · 2026Article
- Roles for specialized secretory epithelial cells in inflammatory bowel disease.Current opinion in gastroenterology · 2026Review
- Convergence in Coevolved Systems: A Two-Axis Filter for Biomimetic Transferability.Biomimetics (Basel, Switzerland) · 2026Article
- Host insulin hijacking by a nematode receptor mediates developmental plasticity and sex ratio shifts.Nature communications · 2026Article
- Immunomodulatory effects of nematode-microbiota interactions in cancer therapy.Frontiers in immunology · 2026Review
- Review
- Isolation ofF1000Research · 2026Article
- Wild edible plants of Bhutan: Diversity, use patterns, and motivations for consumption.PloS one · 2026Article
- Helminths as architects of trained tolerance: implications for human health.Clinical & translational immunology · 2026Review
- Unearthing roundworms: Nematodes as determinants of human health.One health (Amsterdam, Netherlands) · 2025Review
- Soil-Transmitted Helminths and the Intricacies of Immunoregulation: Evidence From Amazonian Ecuador for the Importance of Considering Species-Specific Effects Within the Old Friends Hypothesis.American journal of human biology : the official journal of the Human Biology Council · 2025Article
- Article
215 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCrohn's disease is common in highly industrialised Western countries where helminths are rare and uncommon in less developed areas of the world where most people carry worms. Helminths diminish immune responsiveness in naturally colonised humans and reduce inflammation in experimental colitis. Thus exposure to helminths may help prevent or even ameliorate Crohn's disease.
aimsThe aim of the study was to determine the safety and possible efficacy of the intestinal helminth Trichuris suis in the treatment of patients with active Crohn's disease. PATIENTS: Twenty nine patients with active Crohn's disease, defined by a Crohn's disease activity index (CDAI) > or =220 were enrolled in this open label study.
methodsAll patients ingested 2500 live T suis ova every three weeks for 24 weeks, and disease activity was monitored by CDAI. Remission was defined as a decrease in CDAI to less than 150 while a response was defined as a decrease in CDAI of greater than 100.
resultsAt week 24, 23 patients (79.3%) responded (decrease in CDAI >100 points or CDAI <150) and 21/29 (72.4%) remitted (CDAI <150). Mean CDAI of responders decreased 177.1 points below baseline. Analysis at week 12 yielded similar results. There were no adverse events.
conclusionsThis new therapy may offer a unique, safe, and efficacious alternative for Crohn's disease management. These findings also support the premise that natural exposure to helminths such as T suis affords protection from immunological diseases like Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.